Clinical Trials Browser

Phase 1/2 × Melanoma × denileukin diftitox × Clear all

NCT00945269 2022-11-15

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Phase 1/2 Terminated

Melanoma